Comparison of commercial assays and two-step approach to detect *Clostridioides difficile* in South Africa

**Background:** *Clostridioides difficile* is the number one cause of hospital-acquired diarrhoea. Accurate diagnosis of *C. difficile* is of utmost importance as it guides patient management and infection control practices. Studies evaluating the performance of commercially available nucleic acid amplification tests (NAATs) versus algorithms are lacking in resource-limited settings.

**Objective:** This study assessed the performance of three commercially available tests and a two-step approach for the diagnosis of *C. difficile* infection using toxigenic culture (TC) as the gold standard.

**Methods:** Two hundred and twenty-three non-duplicate loose stool samples were submitted to the National Health Laboratory Service Microbiology Laboratory at Tygerberg Hospital, Cape Town, South Africa, from October 2017 to October 2018. The samples were tested in parallel using the *C. DIFF QUIK CHEK COMPLETE* enzyme immunoassay (EIA) and two NAATs (Xpert *C. difficile* and BD MAX Cdiff), and the results were compared to TC. The performance of a two-step approach consisting of the *C. DIFF QUIK CHEK COMPLETE* followed by the Xpert *C. difficile* was also determined.

**Results:** Of 223 faecal specimens tested, 37 (16.6%) were TC-positive. The sensitivity and specificity of the *C. DIFF QUIK CHEK COMPLETE* were 54.1% and 98.9%; Xpert *C. difficile*, 86.4% and 96.8%; BD MAX Cdiff, 89.2% and 96.8%; and two-step approach, 89.2% and 96.2%.

**Conclusion:** The *C. DIFF QUIK CHEK COMPLETE*, in a two-step approach with the Xpert *C. difficile*, performed similarly to the NAATs on their own and offer advantages in terms of cost and workflow in low-resource settings.

**Keywords:** *Clostridioides difficile; Clostridium difficile; Xpert; BD MAX; QUIK CHEK; toxigenic culture.*

**Introduction**

*Clostridioides* (*Clostridium*) *difficile* is an anaerobic Gram-positive rod capable of forming endospores and producing toxins. *C. difficile* infection is associated with an asymptomatic carrier state, self-limiting diarrhoea, pseudomembranous colitis, and toxic megacolon which can be fatal.1,2 *C. difficile* infection accounts for up to 20% of nosocomial diarrhoea cases worldwide.3 In South Africa, there is very little published data regarding the incidence and prevalence of *C. difficile*; a previous study in patients with diarrhoea reported the prevalence to be 16%.3 In the past two decades, *C. difficile* has also emerged as a cause of community-acquired diarrhoea.4,5 Most *C. difficile* strains produce two major toxins, namely Toxin A, an enterotoxin, encoded by the *tda* gene, and Toxin B, a cytotoxin, encoded by the *tdb* gene. *C. difficile* infection associated with increased severity and mortality has been reported in North America and Europe.5 The *C. difficile* strain responsible for these outbreaks, the hypervirulent 027/NAP1/BL, is characterised by a deletion in the *tcdC* gene (a negative regulator of *tcdA* and *tcdB* expression), resulting in increased production of Toxin A and Toxin B.6 Certain strains of *C. difficile* may produce a binary toxin, *C. difficile* transferase, encoded by *cdtA* and *cdtB*. Data regarding binary toxin conflict, with some studies suggesting its significance is unclear whereas others have shown that it may be associated with a higher mortality rate.7,8

Accurate diagnosis of *C. difficile* infection is essential as it guides patient management and infection control practices. The two diagnostic reference standards for the diagnosis of
C. difficile are toxigenic culture (TC) and the cell culture neutralisation assay; however, these are labour-intensive and have extended turnaround times of 2–3 days.\textsuperscript{10}

Current guidelines recommend a two-step approach: an enzyme immunoassay (EIA), followed by a molecular test to increase the diagnostic yield.\textsuperscript{11} This approach, compared to toxin EIA only, is much more sensitive. Algorithm-based testing is recommended to optimise the positive predictive value of laboratory results.\textsuperscript{11} Commercial EIAs utilise monoclonal antibodies to detect glutamate dehydrogenase (GDH), an antigen common to all C. difficile strains irrespective of toxin production, and Toxin A and/or Toxin B (Tox A/B). The C. DIFF QUIK CHEK COMPLETE EIA detects GDH as well as Tox A/B. Commercial nucleic acid amplification tests (NAATs) are usually real-time polymerase chain reaction (PCR) assays which target tcdB.

In this study, the performance of C. DIFF QUIK CHEK COMPLETE (QUIK CHEK) (Alere Techlab, Blacksburg, Virginia, United States) and two commercial NAATs, the Xpert C. difficile (Xpert) (Cepheid, Sunnyvale, California, United States) and BD MAX Cdiff (BDM) (Recton Dickinson, San Jose, California, United States) were compared to TC. The performance of a two-step approach consisting of the QUIK CHEK and Xpert, that is, the current standard of care (SOC) at our institution, was also evaluated.

**Methods**

**Ethical considerations**

Ethics approval was obtained from the Health Research Ethics Committee of Stellenbosch University, Cape Town, South Africa (reference number S17/03/064). A waiver of informed consent was obtained as no patient identifiers were published and no invasive procedures were performed as a result of this study. Only the results of the current SOC tests were reported to physicians. After the results were recorded, a study number was assigned to the specimen and all patient identifiers were removed.

**Study design**

This was a prospective diagnostic test accuracy study comparing three different assays, namely the QUIK CHEK, Xpert and BDM, to TC (reference method) for the detection of toxigenic C. difficile in faecal samples. The performance of the current SOC (a two-step approach consisting of the QUIK CHEK and Xpert), at our institution was also compared to TC. A composite reference standard (CRS) analysis was performed to account for limitations in TC as a reference method (Supplementary Material).\textsuperscript{12} The CRS composite positive was defined as TC-positive or positive by two commercial assays in a TC-negative sample.

**Sample size**

Tygerberg Hospital near Cape Town, South Africa, is a 1380-bed tertiary hospital which delivers specialist services to approximately half the population of the Western Cape province (total population 6.2 million). The Microbiology Laboratory of the National Health Laboratory Service at Tygerberg Hospital performs C. difficile testing on patient samples from Tygerberg Hospital as well as peripheral hospitals and clinics within the Tygerberg drainage area. Assuming a C. difficile prevalence of 16% based on previous studies, and using a 95% confidence interval with a 5% error rate on both sides, a sample size of 207 was calculated using the Open Epi sample size calculator (G Dean & KM Sullivan, Atlanta, Georgia, United States).\textsuperscript{13}

**Sample processing**

Non-duplicate loose stool samples (defined as taking the shape of the container) from adult and paediatric patients older than two years of age submitted to the National Health Laboratory Service Microbiology Laboratory at Tygerberg Hospital from October 2017 to October 2018 for routine C. difficile testing were tested in parallel with the four assays. None of the samples was frozen and thawed prior to testing. In the rare event that samples could not be tested on the day of collection, they were kept at 2 °C – 8 °C and processed within 48 h of collection.

The QUIK CHEK EIA was performed as per instructions provided by the manufacturer and read by multiple laboratory technologists as part of their routine daily work. The results were interpreted as follows: GDH-positive and Tox A/B-positive samples were regarded as positive, GDH-negative and Tox A/B-negative samples were regarded as negative, and GDH-positive and Tox A/B-negative samples were regarded as negative.

The Xpert NAAT was performed as per the instructions of the manufacturer. The test was interpreted as positive for toxigenic C. difficile if the cytotoxin gene (tcdB) was detected within the valid cycle threshold range and above the minimum endpoint setting, and as toxigenic C. difficile negative if the tcdB gene was not detected, provided the sample processing control and probe check controls met the manufacturer’s requirements. Testing was repeated on any samples with invalid or error results due to failure of the sample processing control or probe check controls.

The BDM NAAT was performed by following the instructions of the manufacturer. Test results were automatically interpreted by the BDM instrument. Positive, negative and unresolved results were based on the target’s and sample processing control’s amplification status. The test was interpreted as toxigenic C. difficile positive if the cytotoxin gene (tcdB) was detected within the valid cycle threshold range and above the minimum endpoint setting, and as toxigenic C. difficile negative if the tcdB gene was not detected, provided the sample processing and probe check controls met the manufacturer’s requirements. Indeterminate and incomplete results are obtained when the BDM system fails. Any unresolved, indeterminate and incomplete samples were repeated.
The two-step algorithm was performed as follows: The QUIK CHEK was done and samples that were GDH-positive and Tox A/B-positive were regarded as positive; GDH-negative and Tox A/B-negative samples were regarded as negative. Samples that were GDH-positive and Tox A/B-negative were interpreted in conjunction with the Xpert results to establish if toxin genes were present or absent.

Toxigenic culture was used as the reference method and performed by culturing C. difficile from stool samples on chromID C. diff agar (bioMérieux, Marcy l’Etoile, France), a differential and selective medium, followed by testing for the organism’s ability to produce toxin by PCR. Inoculated plates were incubated at an anaerobic sachet, AnaeroPack-Anaero (Mitsubishi Gas Chemical Company, Inc., Tokyo, Japan) and incubated at 35 ºC. After 48 h of incubation, the plates were examined for grey and black colonies; if none were present, the culture was considered negative for C. difficile. A multiplex PCR was performed on a streak of grey and black colonies to detect the C. difficile-specific tpi gene, as well as the tcdA and tcdB genes. Cultures that were PCR-positive for the tpi and tcdB genes were considered TC-positive, while those that were PCR-negative for the tpi or tcdB genes were considered TC-negative. In humans, the tcdA gene has been reported in tcdB-positive C. difficile strains only.

Statistical analysis
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for each assay against both TC and the CRS using Epicalc 2000 version 1.00 software (Brixton Books, London, England).

Results
A total of 223 samples were included in the study. Of these, 37 (16.6%) were TC-positive and 19/37 (51.4%) were also positive from all three commercial assays. The SOC positivity rate was 17.9% (40/223).

The QUIK CHEK was GDH-pos in 45/223 (20.2%) samples. Twenty-two of the 45 samples (48.9%) were Tox A/B-pos, of which 20/22 (91%) were also TC-positive. Of the 23 GDH-pos samples that were Tox A/B-neg, 11 (47.8%) were TC-positive (Table 1).

Thirty-eight of the 223 stools (17%) tested positive by Xpert and 32/38 (84.2%) were confirmed as positive by TC. None of the samples was positive for the binary toxin or epidemic 027/NAP1/BI strain. Of the 185 Xpert-negative stools, 180 (97.3%) were confirmed as negative by TC, while 5/185 (2.7%) Xpert-negative samples were TC-positive (Table 1). The BDM detected 39/223 (17.5%) positive stool samples; 33/39 (84.6%) were confirmed by TC. One hundred and eighty of the 184 BDM-negative stools (97.8%) were confirmed as negative using TC, while the other 4/184 (2.2%) were TC-positive. The SOC two-step approach detected 40 positive stool samples, 33 (82.5%) of which were confirmed by TC. Of the 183 SOC-negative stool samples, 179 (97.8%) were confirmed as negative by TC (Table 1).

The QUIK CHEK performed poorly while the Xpert and BDM and the two-step approach had similar sensitivities, specificities, PPV and NPV when compared to TC. Results were also compared to a CRS (Supplementary Table 1).

The Xpert, BDM and two-step approach showed higher sensitivities, specificities and PPV in comparison with the CRS, but the NPV of all the assays were similar.

Discussion
There is a lack of consensus regarding the optimal diagnostic C. difficile laboratory assays. High-quality evidence for the best diagnostic testing strategy is scarce and researchers rarely use either of the two accepted reference standards, that is, cell culture neutralisation assay or TC, for assessment of diagnostic accuracy, but rather their own laboratory-defined CRS criteria. In this study, we determined the diagnostic accuracy of three different commercial assays for the detection of toxigenic C. difficile in stools compared to both TC and a CRS to account for any limitations of the TC.
In this study, the sensitivity of the QUIK CHEK was 54.1%, Xpert was 86.4%, BDM was 89.2% and the two-step approach was 89.2%. The specificity for QUIK CHEK was 98.9%, for Xpert was 96.8%, for BDM was 96.8% and for the two-step approach was 96.2%. The PPV of the QUIK CHEK was 90.9%, Xpert was 84.2%, BDM was 84.6% and the two-step approach was 82.5%. The NPV for QUIK CHEK was 91.5%, Xpert was 97.3%, BDM was 97.8%, and the two-step approach was 97.2%.

Clostridioles difficile toxin EIAs lack sensitivity. All C. difficile contain the GDH antigen, whether toxin genes are present or absent. Glutamate dehydrogenase EIAs have high sensitivities but poor specificities; therefore, an additional test (most commonly a toxin assay) must be performed. The GDH EIA is the first test performed in a two-step or three-step approach where a GDH-positive result is followed by a toxin assay or a NAAT to detect toxin genes. Our findings for the QUIK CHEK showed a sensitivity, specificity, PPV and NPV of 54.1%, 98.9%, 90.9% and 91.5%, respectively. These findings were similar to a study conducted in 2012 in Kuwait comparing the Xpert, QUIK CHEK and TC, which found the sensitivity, specificity, PPV and NPV of the QUIK CHEK to be 53.85%, 100%, 100% and 98.51%, respectively, when using a CRS defined as two tests being in agreement. A 2009–2018 study conducted by Chung and Lee in Korea compared the diagnostic performance of the QUIK CHEK to Xpert as a reference test, with sensitivity, specificity, PPV and NPV of 55.4%, 100.0%, 100.0% and 80.0%, respectively. However, they had a higher prevalence of C. difficile infection (35.9%) than our study population (16.6%), which could explain the difference in PPV (100.0% vs 90.9%). In contrast, a study conducted in 2013–2014 by Seo et al. in Korea, found a lower sensitivity of 45.7% when using either TC or the combination of QUIK CHEK and Xpert as a reference standard.

Nucleic acid amplification tests that target chromosomal toxin genes show high sensitivity and specificity, provide rapid results, and are amenable to both batch and on-demand testing. Reported estimates of sensitivity for NAATs range from 77% to 100% when compared to TC. Specificity ranges from 83% to 100% in comparison to TC. Nucleic acid amplification tests may detect asymptomatic carriage due to possible non-expression of the toxin encoding gene and therefore the clinical specificity may be lower than reported. In their meta-analysis conducted in 2019, Kraft et al. reported an estimated sensitivity of 94% and a specificity of 97% when NAATs were compared to either cell culture neutralisation assay or TC or both in studies where it was specifically stated that stools were only included if conforming to the shape of the container.

In this study, the Xpert had a sensitivity, specificity, PPV and NPV of 86.4%, 96.8%, 84.2% and 97.3% respectively, and the BDM performed similarly showing a sensitivity, specificity, PPV and NPV of 89.2%, 96.8%, 84.6% and 97.8%, respectively. A study by Yoo et al. in Korea found a sensitivity of 82.8% for Xpert and 81.6% for BDM when compared to TC. They attributed the difference in sensitivity between the two tests to a freeze-thaw cycle before the BDM testing. In a study conducted in Germany, Dalpke et al. found a sensitivity, specificity, PPV and NPV of 97.3%, 97.9%, 90.0% and 99.5% for the Xpert and 90.5%, 97.9%, 89.3% and 98.1% for the BDM. In a study conducted 2014–2017 in South Africa demonstrated the impact of diagnostic methods on the diagnosis of C. difficile infection, Nomlomo et al. found a 15.9% positivity rate when using an algorithm approach (consisting of EIA followed by PCR) versus 11.4% and 21.1% when using a toxin EIA and PCR. However, neither of the two accepted references tests was performed as the comparator test in this study. We showed a 16.6% TC positivity rate which is very similar to Nomlomo et al.’s finding using the algorithm approach.

Similar to the sensitivity of 89.2% and specificity of 96.2% for the two-step algorithm approach in our study, Kraft et al.’s meta-analysis found a sensitivity of 89.0% and specificity of 99.0% when comparing GDH/toxin/NAAT algorithms to the TC or cell culture neutralisation assay. In contrast, the Seo et al. study found a higher sensitivity, specificity, PPV and NPV of 94.0%, 100.0%, 100.0% and 100.0% for the two-step approach, which could be attributed to the CRS in this study being either TC-positive or a combination of Xpert- and QUIK CHEK-positive. Our algorithm performed similarly to the Xpert or the BDM alone in terms of sensitivity, specificity, PPV and NPV.

The Xpert, BDM and two-step algorithm performed similarly, with overlapping confidence intervals when compared to TC and CRS. From these findings it is evident that TC is a robust reference test for the statistical measures of sensitivity, specificity, PPV and NPV.

Limitations

Limitations of our study include the use of stool samples conforming to the shape of the container as a surrogate for diarrhoea, as well as not excluding other causes of diarrhoea. In addition, we did not collect pre-analytical data such as prior or current antibiotic use or determine any other risk factors for C. difficile. Post-analytical patient outcome data was also not collected. The sensitivity of lateral flow assays is limited by the dissociation constant of the antibody–antigen conjugate and by user interpretation of the colorimetric read-out. The TC method used in this study did not include heat-shock treatment prior to the inoculation of samples onto media, which may have improved the detection of C. difficile.
Conclusion
The Xpert and BDM assays and two-step approach performed similarly in detecting toxigenic C. difficile in faecal samples. QUIK CHEK cannot be used on its own for the diagnosis of C. difficile due to its poor sensitivity but the SOC two-step approach using QUIK CHEK followed by Xpert showed a similar sensitivity and PPV compared to molecular testing alone. The continued use of the current two-step approach in a resource-limited setting such as South Africa is recommended as it is rapid, easy to perform and reduces cost without compromising diagnostic accuracy.

Acknowledgements
The authors would like to thank BD Diagnostics for partly funding the BDM kits and placement of the BDM instrument, Dr Motala Maloba from the Division of Medical Microbiology, University of the Free State and National Health Laboratory Service, Bloemfontein, South Africa, for her guidance with the study protocol design, Brian Kullin from the Department of Molecular and Cell Biology, University of Cape Town, South Africa, for providing the toxigenic C. difficile control strains, and the Biostatistics Unit, Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa, for their assistance with the statistical analysis of data.

Competing interests
BD Diagnostics provided the BDM instrument for the duration of the study and partially sponsored the BDM kits used in the study; however, BD Diagnostics was not involved in the study design, collection, analysis and interpretation of data, writing of the article, or in the decision to submit the article for publication.

Authors’ contributions
S.S. was involved in the conceptualisation, methodology, validation, investigation, data curation, original draft preparation and funding acquisition. M.N.-F. contributed to the conceptualisation, methodology, software, validation, data curation, reviewing and editing, supervision and project administration. P.N. and C.P. assisted with the methodology, reviewing and editing, supervision and project administration while C.P. also contributed to the visualisation.

Sources of support
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Data availability
Raw data were generated at the National Health Laboratory Service. Derived data supporting the findings of this study are available from the corresponding author, S.S., on request.

Disclaimer
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.

References
1. Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: An ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26(3):604–630. https://doi.org/10.1128/CMR.00016-13
2. Deppestr DD, Aronoff DM. Epidemiology of Clostridium difficile infection. J Pharm Pract. 2013;26(5):464–475. https://doi.org/10.1177/10971847130349521
3. Kullin B, Meggersse R, D’Alton J, et al. Prevalence of gastrointestinal pathogenic bacteria in patients with diarrhoea attending Groote Schuur Hospital, Cape Town, South Africa. S Afr Med J. 2015;105(2):121–125. https://doi.org/10.7196/SAJM.6654
4. Abdullahi VN, Noymer A. Clostridium difficile infection: An emerging cause of death in the twenty-first century. Biodemogr Soc Biol. 2016;62(2):198–207. https://doi.org/10.1080/19485565.2016.1172957
5. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–1084. https://doi.org/10.1016/S0140-6736(05)67420-X
6. Kuiper EJ, Cognaard B, Tüll P, et al. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(Suppl 6):2–18. https://doi.org/10.1111/j.1469-0691.2006.01580.x
7. Di Bella S, Ascenzi P, Sirocki S, Petrosillo N, Di Masi A. Clostridium difficile toxins A and B: Insights into pathogenic properties and extraintestinal effects. Toxins (Basel). 2016;8(5):134. https://doi.org/10.3390/toxins8050134
8. Berry CE, Davies KA, Owens DW, Wilcox MH. Is there a relationship between the presence of the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)? Eur J Clin Microbiol Infect Dis. 2017;36(12):2405–2415. https://doi.org/10.1007/s10096-017-3075-8
9. Gerdin DN, Johnson S, Rupnik M, Aktories K. Clostridium difficile toxin CDT: Mechanism, epidemiology, and potential clinical importance. Gut Microbes. 2014;5(1):15–27. https://doi.org/10.4161/gmic.26854
10. Kraft CS, Parrott JS, Corriss NE, et al. A laboratory medicine best practices systematic review and meta-analysis of nucleic acid amplification tests (NAATs) and algorithms including NAATs for the diagnosis of Clostridiodoses (Clostridiodose) difficile in adults. Clin Microbiol Rev. 2019;32(3):e00032-18. https://doi.org/10.1128/CMR.00032-18
11. McDonald LC, Gerdin DN, Johnson S, et al. Clinical practice guidelines for Clostridiodose difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994. https://doi.org/10.1093/cid/ciy249
12. Tang S, Hemuyi P, Canchola JA, Duncan J. Dual composite reference standards (dCRS) in molecular diagnostic research: A new approach to reduce bias in the presence of imperfect reference. J Biopharm Stat. 2018;28(3):951–965. https://doi.org/10.1080/10543406.2018.1428613
13. See DASK. [homepage on the Internet]. Open Epi: Open Source Epidemiologic Statistics for Public Health, version 3.01. 2013 [cited 2021 Mar 29]. Available from: https://www.openepi.com/Menu/DE_Menu.htm
14. Planche T, Wilcox M. Reference assays for Clostridiodose difficile infection: One or two gold standards? Clin Pathol. 2011;64(1):1–5. https://doi.org/10.1111/j.1469-0691.2010.018035
15. Oldfield EC IV, Oldfield EC III, Johnson DA. Clinical update for the diagnosis and treatment of Clostridiodose difficile infection. World J Gastrointest Pharmacol Ther. 2014;5(1):1–26. https://doi.org/10.4129/wjgtp.v5.i1.1
16. Eckert C, Burchfoer R, Lalande V, Barbut F. Evaluation of the chromogenic agar chromID C. difficile. J Clin Microbiol. 2015;53(3):1002–1004. https://doi.org/10.1128/CMR.02601-12
17. Lemee L, Dhaliwal A, Testelin S, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004;42(12):5710–5714. https://doi.org/10.1128/CMR.42.12.5710-5714.2004
18. Shen A. Clostridium difficile toxins: Mediators of inflammation. J Innate Immun. 2012;4(2):149–158. https://doi.org/10.1159/000332946
19. Jamail W, Pauline EM, Rotmen VI. Comparative performance of the GeneXpert C. difficile PCR assay and C. diff Quik Chek complete kit assay for detection of Clostridium difficile antigen and toxins in symptomatic community-onset infections. Int J Infect Dis. 2014;29:244–248. https://doi.org/10.1016/j.ijid.2014.10.025
20. Chung HS, Lee M. Evaluation of the performance of C. DIFF QUIK CHEK COMPLETE and its usefulness in a hospital setting with a high prevalence of Clostridium difficile infection. J Investig Med. 2017;65(8):88–92. https://doi.org/10.1111/jim.12631
21. Seo JO, Jeong JH, Kim KH, Ahn JY, Park PW, Seo YH. Laboratory diagnosis of Clostridium difficile infection: Comparison of TechLab C. diff Quik Chek complete, Xpert C. difficile, and multistep algorithmic approach. J Clin Lab Anal. 2017;31(6):e22135. https://doi.org/10.1002/jcla.22135
22. Tenover FC, Baron EJ, Peterson LR, Persing DH. Laboratory diagnosis of \textit{Clostridium difficile} infection can molecular amplification methods move us out of uncertainty? J Mol Diagn. 2011;13(6):573–582. https://doi.org/10.1016/j.jmoldx.2011.06.001

23. Crobach MJT, Baktash A, Duszenko N, Kuiper EJ. Diagnostic guidance for \textit{C. difficile} infections. Adv Exp Med Biol. 2018;1050:27–44. https://doi.org/10.1007/978-3-319-72799-8_3

24. Chung HS, Park JS, Shin BM. Laboratory diagnostic methods for \textit{Clostridioides difficile} infection: The first systematic review and meta-analysis in Korea. Ann Lab Med. 2021;41(2):171–180. https://doi.org/10.3343/alm.2021.41.2.171

25. Yoo J, Lee H, Park KG, Lee GD, Park YG, Park YJ. Evaluation of 3 automated real-time PCR (Xpert \textit{C. difficile} assay, BD MAX Cdiff, and IMx \textit{C. difficile} for Abbott m2000 assay) for detecting \textit{Clostridium difficile} toxin gene compared to toxigenic culture in stool specimens. Diagn Microbiol Infect Dis. 2015;83(1):7–10. https://doi.org/10.1016/j.diagmicrobio.2015.05.005

26. Dalpke AH, Hofko M, Zorn M, Zimmermann S. Evaluation of the fully automated BD MAX Cdiff and Xpert \textit{C. difficile} assays for direct detection of \textit{Clostridium difficile} in stool specimens. J Clin Microbiol. 2013;51(6):1906–1908. https://doi.org/10.1128/JCM.00344-13

27. Nomlomo E, Nana T. The impact of diagnostic methods on the diagnosis of \textit{Clostridioides difficile} infection. S Afr Med J. 2020;110(2):135–139. https://doi.org/10.7196/SAMJ.2020.v110i2.13684